Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label tocilizumab study in active rheumatoid arthritis with inadequate response to DMARDs or anti-TNF therapy
IRCT201008312641N3Phase 4Completed
- Sponsor
- Akbarieh
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Akbarieh. Primary endpoints: Safety, Tolerability and 1 more. Started Sep 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on IRCT201008312641N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201008312641N3.